Page 40 - Managed Care News Today

Several analysts have recently updated their ratings and price targets for Centene (NYSE: CNC): 7/31/2023 – Centene had its price target lowered by analysts at Barclays PLC from $86.00 to $85.00. They now have an “overweight” rating on the stock. 7/31/2023 – Centene had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They […]

US lawmakers are seeking faster Medicare Advantage decisions on prior authorization requests, but their legislation could conflict with new Medicare agency rules.

Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.

For the first time, county-level estimates for Alzheimer’s disease prevalence have been released.

As we move through life, it’s essential for us to confront the realities of aging and the need for long-term care. There seems to be a common misunderstanding that various

Moors & Cabot Inc. trimmed its holdings in shares of Centene Co. (NYSE:CNC – Free Report) by 7.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,036 shares of the company’s stock after selling 4,223 shares during the quarter. Moors & Cabot […]

Moors & Cabot Inc. decreased its holdings in shares of Centene Co. (NYSE:CNC – Free Report) by 7.2% during the first quarter, Holdings Channel.com reports. The fund owned 54,036 shares of the company’s stock after selling 4,223 shares during the period. Moors & Cabot Inc.’s holdings in Centene were worth $3,416,000 as of its most […]

The Generic Oncology Drugs Market has witnessed significant growth in recent years, driven by the increasing prevalence of cancer and the growing demand for cost-effective treatment options. Oncology drugs are vital in the management of various types of cancer, and generic versions offer a more affordable alternativ...

Los Angeles Capital Management LLC increased its holdings in Centene Co. (NYSE:CNC – Free Report) by 102.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 724,363 shares of the company’s stock after buying an additional 365,947 shares during the period. Los Angeles Capital Management LLC owned […]

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.